Early results for this INI1-negative trial suggest Tazemetostat harbors promising α-tumor activity; poorly differentiated CH patients (n = 6) enrolled in the dose escalation part of this trial had an objective response rate of 33% [75]. Here, SMARCB1 is linked to cyclic hematopoiesis.